Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SER
SER
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SER News
Navigating the New FDA Era: 2026 Strategic Priorities
Feb 03 2026
Newsfilter
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
Feb 02 2026
Benzinga
DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
Feb 02 2026
Benzinga
Serina Therapeutics Receives FDA Clearance for IND Application
Jan 29 2026
stocktwits
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
Jan 29 2026
Benzinga
Wall Street Focuses on Earnings and Commodity Prices
Jan 29 2026
stocktwits
Serina Therapeutics Receives FDA IND Approval for SER-252
Jan 29 2026
Benzinga
Serina Therapeutics Receives FDA Approval to Advance Parkinson's Disease Treatment
Jan 28 2026
Newsfilter
Serina Therapeutics (SER) Receives NYSE Deficiency Notice for Low Stockholders' Equity
Jan 16 2026
NASDAQ.COM
Serina Therapeutics (NYSE:SER) Faces NYSE Delisting Risk, Must Submit Compliance Plan
Jan 15 2026
seekingalpha
Serina Therapeutics Faces NYSE Delisting Risk with $1.6M Shareholder Equity
Jan 15 2026
Globenewswire
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
Jan 08 2026
Benzinga
Serina Therapeutics Appoints Joshua Thomas as VP of Chemistry to Advance POZ Platform
Dec 11 2025
Globenewswire
Serina Submits FDA Response, Targets First Patient In for Phase 1b Study in Q1 2026
Dec 10 2025
Globenewswire
Serina Submits FDA Response, Targets Q1 2026 for Clinical Trial Start
Dec 10 2025
Newsfilter
Serina Therapeutics Announces Financial Results and Business Highlights for Q3 2025
Nov 13 2025
Newsfilter
Show More News
